AbbVie and REGENXBIO Announce Eye Care Collaboration

AbbVie and REGENXBIO Announce Eye Care Collaboration


Excerpt

AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach of RGX-314 will be led by AbbVie, while REGENXBIO will participate in the U.S. development and commercialization efforts.

Article

AbbVie and REGENXBIO are entering an eye care and gene therapy collaboration to advance the development and commercialisation of RGX-314 for treating wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) among other chronic retinal diseases. 

REGENXBIO will oversee the completion of on-going Phase II trials of the potential one-time gene therapy, which include testing of two separate delivery methods. Costs of further trials will be shared between the two companies.

The agreement entails a commercialization plan for which AbbVie will employ its developmental expertise and infrastructure for the global eye care market, while REGENXBIO will be involved in U.S.-based clinical development, manufacturing and production, and commercialization efforts.

“In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases,” said Tom Hudson, MD, senior vice president, R&D and chief scientific officer at AbbVie.

REGENXBIO will potentially receive up to $1.38 billion in development, regulatory and commercial milestones in addition to a $370 million upfront payment from AbbVie. The deal is expected to be closed by the end of 2021.

REGENXBIO held a webcast and conference call with regards to the announcement on 13th September, 2021. A recording may be accessed within 30 days of the event via the “Investors” section of the REGENXBIO website at www.regenxbio.com

About RGX-314

RGX-314 is encoded with antibody components designed to inhibit the vascular endothelial growth factor (VEGF) pathway which contributes to fluid accumulation in the retina, leading on the chronic retinal conditions. REGENXBIO is studying the one-time administration of RGX-314 to the eye via two different delivery methods.

About Wet AMD

Wet AMD is the occurrence of vision loss due to new, leaky blood vessel formation in the retina and is known to affect almost 2 million people in the United States, Europe and Japan alone. Current standard anti-VEGF therapies help with preventing disease progression but require repeated treatment procedure throughout the lifetime, which tends to be unsustainable for many patients.

About Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged between 24 and 75 years worldwide, affecting approximately 8 million people in the United States itself. DR often progresses to complications like diabetic macular edema (DME) and neovascularization the can lead to blindness. Anti-VEGF treatment, retinal laser or surgical treatment and “watchful waiting” are the current available treatment options.

About AbbVie

AbbVie is a pharmaceutical company researching and developing innovative solutions to serious health issues and medical challenges, and aiming to have an impact in several key therapeutic areas, such as immunology, oncology, and eye care, and via products and services across its Allergan Aesthetics portfolio. For more information, visit www.abbvie.com.

About REGENXBIO Inc.

REGENXBIO is a leader in clinical-stage biotechnology, and is developing gene therapy for curative treatments. Its proprietary NAV Technology Platform is being utilized for advancements in multiple therapeutic areas.

(Source: Abbvie, 13th September 2021)


Excerpt

AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach of RGX-314 will be led by AbbVie, while REGENXBIO will participate in the U.S. development and commercialization efforts.

Article

AbbVie and REGENXBIO are entering an eye care and gene therapy collaboration to advance the development and commercialisation of RGX-314 for treating wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) among other chronic retinal diseases. 

REGENXBIO will oversee the completion of on-going Phase II trials of the potential one-time gene therapy, which include testing of two separate delivery methods. Costs of further trials will be shared between the two companies.

The agreement entails a commercialization plan for which AbbVie will employ its developmental expertise and infrastructure for the global eye care market, while REGENXBIO will be involved in U.S.-based clinical development, manufacturing and production, and commercialization efforts.

“In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases,” said Tom Hudson, MD, senior vice president, R&D and chief scientific officer at AbbVie.

REGENXBIO will potentially receive up to $1.38 billion in development, regulatory and commercial milestones in addition to a $370 million upfront payment from AbbVie. The deal is expected to be closed by the end of 2021.

REGENXBIO held a webcast and conference call with regards to the announcement on 13th September, 2021. A recording may be accessed within 30 days of the event via the “Investors” section of the REGENXBIO website at www.regenxbio.com

About RGX-314

RGX-314 is encoded with antibody components designed to inhibit the vascular endothelial growth factor (VEGF) pathway which contributes to fluid accumulation in the retina, leading on the chronic retinal conditions. REGENXBIO is studying the one-time administration of RGX-314 to the eye via two different delivery methods.

About Wet AMD

Wet AMD is the occurrence of vision loss due to new, leaky blood vessel formation in the retina and is known to affect almost 2 million people in the United States, Europe and Japan alone. Current standard anti-VEGF therapies help with preventing disease progression but require repeated treatment procedure throughout the lifetime, which tends to be unsustainable for many patients.

About Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged between 24 and 75 years worldwide, affecting approximately 8 million people in the United States itself. DR often progresses to complications like diabetic macular edema (DME) and neovascularization the can lead to blindness. Anti-VEGF treatment, retinal laser or surgical treatment and “watchful waiting” are the current available treatment options.

About AbbVie

AbbVie is a pharmaceutical company researching and developing innovative solutions to serious health issues and medical challenges, and aiming to have an impact in several key therapeutic areas, such as immunology, oncology, and eye care, and via products and services across its Allergan Aesthetics portfolio. For more information, visit www.abbvie.com.

About REGENXBIO Inc.

REGENXBIO is a leader in clinical-stage biotechnology, and is developing gene therapy for curative treatments. Its proprietary NAV Technology Platform is being utilized for advancements in multiple therapeutic areas.

(Source: Abbvie, 13th September 2021)


Excerpt

AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach of RGX-314 will be led by AbbVie, while REGENXBIO will participate in the U.S. development and commercialization efforts.

Article

AbbVie and REGENXBIO are entering an eye care and gene therapy collaboration to advance the development and commercialisation of RGX-314 for treating wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) among other chronic retinal diseases. 

REGENXBIO will oversee the completion of on-going Phase II trials of the potential one-time gene therapy, which include testing of two separate delivery methods. Costs of further trials will be shared between the two companies.

The agreement entails a commercialization plan for which AbbVie will employ its developmental expertise and infrastructure for the global eye care market, while REGENXBIO will be involved in U.S.-based clinical development, manufacturing and production, and commercialization efforts.

“In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases,” said Tom Hudson, MD, senior vice president, R&D and chief scientific officer at AbbVie.

REGENXBIO will potentially receive up to $1.38 billion in development, regulatory and commercial milestones in addition to a $370 million upfront payment from AbbVie. The deal is expected to be closed by the end of 2021.

REGENXBIO held a webcast and conference call with regards to the announcement on 13th September, 2021. A recording may be accessed within 30 days of the event via the “Investors” section of the REGENXBIO website at www.regenxbio.com

About RGX-314

RGX-314 is encoded with antibody components designed to inhibit the vascular endothelial growth factor (VEGF) pathway which contributes to fluid accumulation in the retina, leading on the chronic retinal conditions. REGENXBIO is studying the one-time administration of RGX-314 to the eye via two different delivery methods.

About Wet AMD

Wet AMD is the occurrence of vision loss due to new, leaky blood vessel formation in the retina and is known to affect almost 2 million people in the United States, Europe and Japan alone. Current standard anti-VEGF therapies help with preventing disease progression but require repeated treatment procedure throughout the lifetime, which tends to be unsustainable for many patients.

About Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged between 24 and 75 years worldwide, affecting approximately 8 million people in the United States itself. DR often progresses to complications like diabetic macular edema (DME) and neovascularization the can lead to blindness. Anti-VEGF treatment, retinal laser or surgical treatment and “watchful waiting” are the current available treatment options.

About AbbVie

AbbVie is a pharmaceutical company researching and developing innovative solutions to serious health issues and medical challenges, and aiming to have an impact in several key therapeutic areas, such as immunology, oncology, and eye care, and via products and services across its Allergan Aesthetics portfolio. For more information, visit www.abbvie.com.

About REGENXBIO Inc.

REGENXBIO is a leader in clinical-stage biotechnology, and is developing gene therapy for curative treatments. Its proprietary NAV Technology Platform is being utilized for advancements in multiple therapeutic areas.

(Source: Abbvie, 13th September 2021)


Excerpt

AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach of RGX-314 will be led by AbbVie, while REGENXBIO will participate in the U.S. development and commercialization efforts.

Article

AbbVie and REGENXBIO are entering an eye care and gene therapy collaboration to advance the development and commercialisation of RGX-314 for treating wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) among other chronic retinal diseases. 

REGENXBIO will oversee the completion of on-going Phase II trials of the potential one-time gene therapy, which include testing of two separate delivery methods. Costs of further trials will be shared between the two companies.

The agreement entails a commercialization plan for which AbbVie will employ its developmental expertise and infrastructure for the global eye care market, while REGENXBIO will be involved in U.S.-based clinical development, manufacturing and production, and commercialization efforts.

“In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases,” said Tom Hudson, MD, senior vice president, R&D and chief scientific officer at AbbVie.

REGENXBIO will potentially receive up to $1.38 billion in development, regulatory and commercial milestones in addition to a $370 million upfront payment from AbbVie. The deal is expected to be closed by the end of 2021.

REGENXBIO held a webcast and conference call with regards to the announcement on 13th September, 2021. A recording may be accessed within 30 days of the event via the “Investors” section of the REGENXBIO website at www.regenxbio.com

About RGX-314

RGX-314 is encoded with antibody components designed to inhibit the vascular endothelial growth factor (VEGF) pathway which contributes to fluid accumulation in the retina, leading on the chronic retinal conditions. REGENXBIO is studying the one-time administration of RGX-314 to the eye via two different delivery methods.

About Wet AMD

Wet AMD is the occurrence of vision loss due to new, leaky blood vessel formation in the retina and is known to affect almost 2 million people in the United States, Europe and Japan alone. Current standard anti-VEGF therapies help with preventing disease progression but require repeated treatment procedure throughout the lifetime, which tends to be unsustainable for many patients.

About Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged between 24 and 75 years worldwide, affecting approximately 8 million people in the United States itself. DR often progresses to complications like diabetic macular edema (DME) and neovascularization the can lead to blindness. Anti-VEGF treatment, retinal laser or surgical treatment and “watchful waiting” are the current available treatment options.

About AbbVie

AbbVie is a pharmaceutical company researching and developing innovative solutions to serious health issues and medical challenges, and aiming to have an impact in several key therapeutic areas, such as immunology, oncology, and eye care, and via products and services across its Allergan Aesthetics portfolio. For more information, visit www.abbvie.com.

About REGENXBIO Inc.

REGENXBIO is a leader in clinical-stage biotechnology, and is developing gene therapy for curative treatments. Its proprietary NAV Technology Platform is being utilized for advancements in multiple therapeutic areas.

(Source: Abbvie, 13th September 2021)


Excerpt

AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach of RGX-314 will be led by AbbVie, while REGENXBIO will participate in the U.S. development and commercialization efforts.

Article

AbbVie and REGENXBIO are entering an eye care and gene therapy collaboration to advance the development and commercialisation of RGX-314 for treating wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) among other chronic retinal diseases. 

REGENXBIO will oversee the completion of on-going Phase II trials of the potential one-time gene therapy, which include testing of two separate delivery methods. Costs of further trials will be shared between the two companies.

The agreement entails a commercialization plan for which AbbVie will employ its developmental expertise and infrastructure for the global eye care market, while REGENXBIO will be involved in U.S.-based clinical development, manufacturing and production, and commercialization efforts.

“In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases,” said Tom Hudson, MD, senior vice president, R&D and chief scientific officer at AbbVie.

REGENXBIO will potentially receive up to $1.38 billion in development, regulatory and commercial milestones in addition to a $370 million upfront payment from AbbVie. The deal is expected to be closed by the end of 2021.

REGENXBIO held a webcast and conference call with regards to the announcement on 13th September, 2021. A recording may be accessed within 30 days of the event via the “Investors” section of the REGENXBIO website at www.regenxbio.com

About RGX-314

RGX-314 is encoded with antibody components designed to inhibit the vascular endothelial growth factor (VEGF) pathway which contributes to fluid accumulation in the retina, leading on the chronic retinal conditions. REGENXBIO is studying the one-time administration of RGX-314 to the eye via two different delivery methods.

About Wet AMD

Wet AMD is the occurrence of vision loss due to new, leaky blood vessel formation in the retina and is known to affect almost 2 million people in the United States, Europe and Japan alone. Current standard anti-VEGF therapies help with preventing disease progression but require repeated treatment procedure throughout the lifetime, which tends to be unsustainable for many patients.

About Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged between 24 and 75 years worldwide, affecting approximately 8 million people in the United States itself. DR often progresses to complications like diabetic macular edema (DME) and neovascularization the can lead to blindness. Anti-VEGF treatment, retinal laser or surgical treatment and “watchful waiting” are the current available treatment options.

About AbbVie

AbbVie is a pharmaceutical company researching and developing innovative solutions to serious health issues and medical challenges, and aiming to have an impact in several key therapeutic areas, such as immunology, oncology, and eye care, and via products and services across its Allergan Aesthetics portfolio. For more information, visit www.abbvie.com.

About REGENXBIO Inc.

REGENXBIO is a leader in clinical-stage biotechnology, and is developing gene therapy for curative treatments. Its proprietary NAV Technology Platform is being utilized for advancements in multiple therapeutic areas.

(Source: Abbvie, 13th September 2021)


Excerpt

AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach of RGX-314 will be led by AbbVie, while REGENXBIO will participate in the U.S. development and commercialization efforts.

Article

AbbVie and REGENXBIO are entering an eye care and gene therapy collaboration to advance the development and commercialisation of RGX-314 for treating wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) among other chronic retinal diseases. 

REGENXBIO will oversee the completion of on-going Phase II trials of the potential one-time gene therapy, which include testing of two separate delivery methods. Costs of further trials will be shared between the two companies.

The agreement entails a commercialization plan for which AbbVie will employ its developmental expertise and infrastructure for the global eye care market, while REGENXBIO will be involved in U.S.-based clinical development, manufacturing and production, and commercialization efforts.

“In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases,” said Tom Hudson, MD, senior vice president, R&D and chief scientific officer at AbbVie.

REGENXBIO will potentially receive up to $1.38 billion in development, regulatory and commercial milestones in addition to a $370 million upfront payment from AbbVie. The deal is expected to be closed by the end of 2021.

REGENXBIO held a webcast and conference call with regards to the announcement on 13th September, 2021. A recording may be accessed within 30 days of the event via the “Investors” section of the REGENXBIO website at www.regenxbio.com

About RGX-314

RGX-314 is encoded with antibody components designed to inhibit the vascular endothelial growth factor (VEGF) pathway which contributes to fluid accumulation in the retina, leading on the chronic retinal conditions. REGENXBIO is studying the one-time administration of RGX-314 to the eye via two different delivery methods.

About Wet AMD

Wet AMD is the occurrence of vision loss due to new, leaky blood vessel formation in the retina and is known to affect almost 2 million people in the United States, Europe and Japan alone. Current standard anti-VEGF therapies help with preventing disease progression but require repeated treatment procedure throughout the lifetime, which tends to be unsustainable for many patients.

About Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged between 24 and 75 years worldwide, affecting approximately 8 million people in the United States itself. DR often progresses to complications like diabetic macular edema (DME) and neovascularization the can lead to blindness. Anti-VEGF treatment, retinal laser or surgical treatment and “watchful waiting” are the current available treatment options.

About AbbVie

AbbVie is a pharmaceutical company researching and developing innovative solutions to serious health issues and medical challenges, and aiming to have an impact in several key therapeutic areas, such as immunology, oncology, and eye care, and via products and services across its Allergan Aesthetics portfolio. For more information, visit www.abbvie.com.

About REGENXBIO Inc.

REGENXBIO is a leader in clinical-stage biotechnology, and is developing gene therapy for curative treatments. Its proprietary NAV Technology Platform is being utilized for advancements in multiple therapeutic areas.

(Source: Abbvie, 13th September 2021)


Excerpt

AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach of RGX-314 will be led by AbbVie, while REGENXBIO will participate in the U.S. development and commercialization efforts.

Article

AbbVie and REGENXBIO are entering an eye care and gene therapy collaboration to advance the development and commercialisation of RGX-314 for treating wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) among other chronic retinal diseases. 

REGENXBIO will oversee the completion of on-going Phase II trials of the potential one-time gene therapy, which include testing of two separate delivery methods. Costs of further trials will be shared between the two companies.

The agreement entails a commercialization plan for which AbbVie will employ its developmental expertise and infrastructure for the global eye care market, while REGENXBIO will be involved in U.S.-based clinical development, manufacturing and production, and commercialization efforts.

“In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases,” said Tom Hudson, MD, senior vice president, R&D and chief scientific officer at AbbVie.

REGENXBIO will potentially receive up to $1.38 billion in development, regulatory and commercial milestones in addition to a $370 million upfront payment from AbbVie. The deal is expected to be closed by the end of 2021.

REGENXBIO held a webcast and conference call with regards to the announcement on 13th September, 2021. A recording may be accessed within 30 days of the event via the “Investors” section of the REGENXBIO website at www.regenxbio.com

About RGX-314

RGX-314 is encoded with antibody components designed to inhibit the vascular endothelial growth factor (VEGF) pathway which contributes to fluid accumulation in the retina, leading on the chronic retinal conditions. REGENXBIO is studying the one-time administration of RGX-314 to the eye via two different delivery methods.

About Wet AMD

Wet AMD is the occurrence of vision loss due to new, leaky blood vessel formation in the retina and is known to affect almost 2 million people in the United States, Europe and Japan alone. Current standard anti-VEGF therapies help with preventing disease progression but require repeated treatment procedure throughout the lifetime, which tends to be unsustainable for many patients.

About Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged between 24 and 75 years worldwide, affecting approximately 8 million people in the United States itself. DR often progresses to complications like diabetic macular edema (DME) and neovascularization the can lead to blindness. Anti-VEGF treatment, retinal laser or surgical treatment and “watchful waiting” are the current available treatment options.

About AbbVie

AbbVie is a pharmaceutical company researching and developing innovative solutions to serious health issues and medical challenges, and aiming to have an impact in several key therapeutic areas, such as immunology, oncology, and eye care, and via products and services across its Allergan Aesthetics portfolio. For more information, visit www.abbvie.com.

About REGENXBIO Inc.

REGENXBIO is a leader in clinical-stage biotechnology, and is developing gene therapy for curative treatments. Its proprietary NAV Technology Platform is being utilized for advancements in multiple therapeutic areas.

(Source: Abbvie, 13th September 2021)

Comments

Leave A Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

bag